Generation of Anti-complement “Prodrugs”
Open Access
- 1 September 2003
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (38) , 36068-36076
- https://doi.org/10.1074/jbc.m306351200
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Tailoring anti-complement therapeuticsBiochemical Society Transactions, 2002
- Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-lifein vivoClinical and Experimental Immunology, 2002
- Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site.: Efficient aggrecanase catabolism may depend on multiple substrate interactionsMatrix Biology, 2000
- Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage PatternsJournal of Biological Chemistry, 2000
- Mechanisms involved in cartilage proteoglycan catabolismMatrix Biology, 2000
- Differential Expression of Aggrecanase and Matrix Metalloproteinase Activity in Chondrocytes Isolated from Bovine and Porcine Articular CartilageJournal of Biological Chemistry, 1998
- Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptidesBiopolymers, 1996
- The structural requirements for complement activation by IgG: does it hinge on the hinge?Immunology Today, 1995
- Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assaysBiochemistry, 1992
- Structure-function relationships of the complement componentsImmunology Today, 1989